Evolus has announced it has entered into a definitive agreement with Symatese to be the exclusive distributor in the United Kingdom and Europe of four unique dermal fillers.
The product line is in late-stage development with anticipated regulatory clearances in second half of 2024 and commercialisation under the brand name Estyme fillers (pronounced “esteem”) in 2025.
It is the second agreement made with Symatese this year – with the first obtaining exclusive distribution rights to the same product line in the US, where it will be commercialised under the brand name Evolysse in 2025. As a result of the geographic expansion of the filler line, the company has doubled its total addressable international market (outside the US).
“Today’s announcement marks yet another crucial step in our global expansion to offer a multi-product portfolio to our customers and the patients they treat. The addition of the Estyme facial fillers in the UK and Europe will complement the recent launch of Nuceiva, our flagship neurotoxin, which has been met with very strong interest and growing demand from customers,” said David Moatazedi, president, and chief executive of Evolus. “We are increasingly optimistic about the near-term potential that the next-generation technology in the Evolysse and Estyme fillers lines will offer customers in the fast-growing facial HA market. We are confident that these innovative new products, along with our growing brand loyalty to our market-leading neurotoxin and the associated digital infrastructure and distribution platform will drive our topline growth for years to come.”
Neurotoxins and dermal fillers are the two most requested medical aesthetic procedures in the US and Europe. The two distribution agreements for the Evolysse/Estyme fillers portfolio will grant Evolus the ability to offer a complete range of filler solutions to cover mid-face, nasolabial folds, and lip indications in Europe, plus an eye product line in the US.
As part of the new agreement, Evolus will be licensing its neurotoxin, Nuceiva (botulinum toxin type A), to Symatese for distribution in France, marking the fifth European market that Evolus has now entered. In addition, Evolus will sub-license its distribution rights for the Estyme fillers line to a Symatese subsidiary for distribution in France.
“We are extremely excited to expand our partnership with Evolus beyond the US to now include the UK and Europe. We firmly believe in the growth opportunity for our innovative filler lines in these markets and also in Evolus’ accelerating growth in the neurotoxin market. As such, we have agreed to receive payment for the license for the European markets in the form of Evolus’ common shares. We have complete confidence in the Evolus team, and we look forward to pursuing this exceptional growth opportunity together,” said Jean-Paul Gérardin, chief executive of Symatese.
